Discontinued — last reported Q4 '25
Influvac ® — Net Sales
Viatris Influvac ® — Net Sales decreased by 49.3% to $63.60M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 20.7%, from $52.70M to $63.60M. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase suggests stronger seasonal demand or improved market share for the vaccine, while a decrease may indicate lower vaccination uptake, increased competition, or supply chain constraints.
Detailed definition
This metric represents the total revenue generated from the sale of the Influvac influenza vaccine product line after ac...
Peer comparison
Comparable to seasonal vaccine revenue metrics reported by pharmaceutical peers like GSK, Sanofi, or AstraZeneca, which also experience significant year-over-year seasonality.
vtrs_segment_influvac_net_salesHistorical Data
| Q3 '21 | Q4 '21 | Q3 '22 | Q4 '22 | Q3 '23 | Q4 '23 | Q3 '24 | Q4 '24 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Value | $161.20M | $134.00M | $159.30M | $47.20M | $137.20M | $54.90M | $121.30M | $52.70M | $125.40M | $63.60M |
| QoQ Change | — | -16.9% | +18.9% | -70.4% | +190.7% | -60.0% | +120.9% | -56.6% | +138.0% | -49.3% |
| YoY Change | — | — | -1.2% | -64.8% | -13.9% | +16.3% | -11.6% | -4.0% | +3.4% | +20.7% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Viatris's influvac ® — net sales?
- Viatris (VTRS) reported influvac ® — net sales of $63.60M in Q4 2025.
- How has Viatris's influvac ® — net sales changed year-over-year?
- Viatris's influvac ® — net sales increased by 20.7% year-over-year, from $52.70M to $63.60M.
- What does influvac ® — net sales mean?
- The total revenue earned from selling the Influvac influenza vaccine.